Findings

What do systematic reviews say?

240 questions · 247 findings · 23 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 35 · 14.2%GRADE not reported 13 · 5.3%Very low 50 · 20.2%Low 71 · 28.7%Moderate 65 · 26.3%High 13 · 5.3%

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection

Pegylated interferon alpha‐2a showed no clear difference in relapse(recurrence after stopping) compared with standard interferon (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 0.72 [0.41, 1.25]
1 study · 38 participants
Low

Pegylated (PEG) interferon alpha‐2a vs standard interferon

End‐of‐treatment response · patients on HD with HCV infection

Pegylated interferon alpha‐2a may leads to higher end‐of‐treatment response compared with standard interferon (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.53 [1.09, 2.15]
1 study · 50 participants
Low

Pegloticase every two weeks (biweekly) vs placebo

Proportion with complete resolution of a target tophus · participants with tophi in gout

Pegloticase every two weeks (biweekly) probably leads to higher proportion with complete resolution of tophi compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 5.45 [1.38, 21.54]
1 study · 79 participants
Moderate

Pegloticase every two weeks (biweekly) vs placebo

Joint pain reduction ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pegloticase every two weeks (biweekly) vs placebo

Quality of life ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pegloticase every two weeks (biweekly) vs placebo

Serum urate normalisation ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pegloticase every two weeks (biweekly) vs placebo

Function ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pegloticase every two weeks (biweekly) vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 7.59 [1.04, 55.55]
1 study · 128 participants
Moderate

Pegloticase every two weeks (biweekly) vs placebo

Total adverse events · participants with tophi in gout

Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 0.99 [0.91, 1.07]
1 study · 128 participants
Moderate

HAART + pegylated liposomal doxorubicin vs HAART + liposomal daunorubicin

Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 46 participants
Moderate

HAART + pegylated liposomal doxorubicin vs HAART alone

Clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + pegylated liposomal doxorubicin showed no clear difference in clinical response compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 9 [0.61, 133.08]
1 study · 10 participants
Moderate

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single dose) vs Granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple doses)

Oral mucositis (any severity) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in oral mucositis (any severity) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Children
RR 1.02 [0.82, 1.27]
1 study · 61 participants
GRADE not reported

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single dose) vs Granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple doses)

Normalcy of diet (total parenteral nutrition) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in normalcy of diet (total parenteral nutrition) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Children
RR 1.00 [0.94, 1.06]
1 study · 61 participants
GRADE not reported

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single dose) vs Granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple doses)

Oral mucositis (moderate to severe) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in oral mucositis (moderate to severe) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Children
RR 0.78 [0.55, 1.11]
1 study · 61 participants
GRADE not reported

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 164 participants
Moderate

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

Change in untransformed GA lesion size from baseline at 1 year (mmÂ²)Â · adults with GA due to AMD

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 967 participants
High

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham; GRADE not reported.

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
RR 4.47 [0.41, 48.98]
3 studies · 1003 participants
GRADE not reported

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
RR 3.79 [0.42, 34.05]
3 studies · 1003 participants
Moderate

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD

The review found no eligible studies for this question.

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham

Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD

1 finding from 1 review

Complement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 164 participants
Moderate